Savara to present Phase 3 IMPALA-2 molgramostim data in autoimmune pulmonary alveolar proteinosis at ERS 2026

Reuters2026/08/24 20:06

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

Savara flagged new Phase 3 IMPALA-2 data for molgramostim in autoimmune pulmonary alveolar proteinosis at the ERS Congress, Sept. 5-9, 2026.
Results will be presented in the future, including an oral session on Sept. 6 covering longer-term efficacy and safety from the open-label period.
Data indicate sustained gains in lung function, exercise capacity, and quality of life, supporting molgramostim as a potential long-term treatment option.
Separate analyses point to reductions in disease-related biomarkers, suggesting the therapy may address underlying disease biology.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Savara Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 202608241605BIZWIRE_USPR_____20260824_BW428528) on August 24, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

Savara to present Phase 3 IMPALA-2 molgramostim data in autoimmune pulmonary alveolar proteinosis at ERS 2026

You may also like

Crypto prices